Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
This analysis describes the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in patients enrolled in the Prospective Antifungal Therapy Alliance (PATH Alliance) registry from 2004 to 2008. A total of 2,496 patients with non-albicans species of Candida isolates were identified. The identified species were C. glabrata (46.4%), C. parapsilosis (24.7%), C. tropicalis (13.9%), C. krusei (5.5%), C. lusitaniae (1.6%), C. dubliniensis (1.5%) and C. guilliermondii (0.4%); 111 infections involved two or more species of Candida (4.4%). Non-albicans species accounted for more than 50% of all cases of invasive candidiasis in 15 of the 24 sites (62.5%) that contributed more than one case to the survey. Among solid organ transplant recipients, patients with non-transplant surgery, and patients with solid tumors, the most prevalent non-albicans species was C. glabrata at 63.7%, 48.0%, and 53.8%, respectively. In 1,883 patients receiving antifungal therapy on day 3, fluconazole (30.5%) and echinocandins (47.5%) were the most frequently administered monotherapies. Among the 15 reported species, 90-day survival was highest for patients infected with either C. parapsilosis (70.7%) or C. lusitaniae (74.5%) and lowest for patients infected with an unknown species (46.7%) or two or more species (53.2%). In conclusion, this study expands the current knowledge of the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in North America. The variability in species distribution in these centers underscores the importance of local epidemiology in guiding the selection of antifungal therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“although C. glabrata has been reported to represent more than 30% of the non-albicans Candida in some geographic areas [4, 6–9].”
From Invasive candidiasis species distribution and trends, United States, 2009-2017 (2021) · cites this paper as [7]
In the citing paper
“C. glabrata bloodstream infections are commonly found in elderly individuals, diabetic patients and solid organ transplant recipients [6,8,9].”
From Candida glabrata: A Lot More Than Meets the Eye (2019) · cites this paper as [8]
In the citing paper
“The emergence of resistant strains, including those becoming resistant to multiple drugs, has been increasingly reported in recent years [14,15,16].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“More than 30 species of Candida have been reported to cause IC [3–6].”
BackgroundSelf-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 2×
“parapsilosis, the early removal of central venous catheters remains an important principle in the management of candidemia caused by this species [29].”
BackgroundSelf-citationAscioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331 · cited 1×
“from blood cultures and other forms of IC (proven or probable) were defined according to the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group criteria [33].”
MethodCornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217 · cited 4×
“On reviewing the approaches to antifungal therapy reported by the participating centers, several appear to be at odds with current consensus guidelines [28–30] and reported susceptibility profiles in the literature [14,21].”
BackgroundResultInfluentialEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901 · cited 2×
“7%, in keeping with other reports [1].”
BackgroundSelf-citationAndes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793 · cited 2×
“Indeed Andes et al [39] found in a patient-level T a b le 1 .”
BackgroundSelf-citationAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · cited 2×
“glabrata with co-resistance to both azoles and echinocandins in some medical centers [12,13,20].”
BackgroundSelf-citationThe changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance
Hong Nguyen, M., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R., Wagener, M. M., Rinaldi, M. G., & Yu, V. L. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00010-0 · Cited by 758 · cited 2×
“glabrata has been reported by other investigators [23–27]; however, a recent systematic review by Falagas et al.”
BackgroundResultPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718 · cited 1×
“While some of these species have been designated as ‘emerging’ species, the apparent increased detection of these species may simply reflect the more vigorous efforts to identify clinical isolates of Candida to the species level in recent years [6,20,46].”
BackgroundSelf-citationPfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 694 · cited 3×
“4% of all N-CA isolates in this registry, there are several that merit attention either because they have been shown to cause clusters of infection in the hospital setting, because they are frequently misidentified by conventional methods or represent ‘cryptic’ species, or because they exhibit decreased susceptibility…”
BackgroundSelf-citation
Research works printed but not linked: 1
- 31. Horn D, Neofytos D (2007) Contemporary patterns in the use of antifungal agents in the treatment of invasive fungal infections: perspectives from registries and databases. Curr Fungal Infect Rep 1: 72-78.
Cited by
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Self-citationThe Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
Antimicrobial Agents and Chemotherapy
(2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac · Cited by 485
de Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A. J. O., de Sousa Cartágenes, M. D. S., Filho, A. K. D. B., do Nascimento, F. R. F., Ramos, R. M., Pires, E. R. R. B., de Andrade, M. S., Rocha, F. M. G., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01351 · Cited by 350
“Candida species, opportunistic pathogens, are a major cause of morbidity and mortality worldwide and thus represents a serious threat to public health (Pfaller et al., 2014; Matthaiou et al., 2015; Pappas et al., 2016).”
BackgroundDadar, M., Tiwari, R., Karthik, K., Chakraborty, S., Shahali, Y., & Dhama, K. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.02.028 · Cited by 332
Candida parapsilosis: from genes to the bedside
Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., Turner, S. A., Butler, G., Vágvölgyi, C., & Gácser, A. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00111-18 · Cited by 327
“A nationwide study provided by Pfaller et al. further showed that among NAC species, C. parapsilosis accounts for most of the invasive candidiasis cases in children ( 9 years old) and in neonates in North America (23).”
BackgroundInfluentialThe global burden of fungal diseases
Vallabhaneni, S., Mody, R. K., Walker, T., & Chiller, T. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.004 · Cited by 292
Roscetto, E., Contursi, P., Vollaro, A., Fusco, S., Notomista, E., & Catania, M. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-35530-0 · Cited by 272
Ahmad, S., & Alfouzan, W. (2021) · Microorganisms · doi:10.3390/microorganisms9040807 · Cited by 269
Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris
Chatterjee, S., Alampalli, S. V., Nageshan, R. K., Chettiar, S. T., Joshi, S., & Tatu, U. S. (2015) · BMC Genomics · doi:10.1186/s12864-015-1863-z · Cited by 247
“However the rising number of immunocompromised people, unwarranted use of multiple broad spectrum antibiotics and the advent of implanted medical devices [5] has paved the way for rare non albicans Candida species [6] as agents of invasive mycoses and nosocomial bloodstream infections [7].”
Schmiedel, Y., & Zimmerli, S. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14281 · Cited by 218
ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients
Martin-Loeches, I., Antonelli, M., Cuenca-Estrella, M., Dimopoulos, G., Einav, S., De Waele, J. J., Garnacho-Montero, J., Kanj, S. S., Machado, F. R., Montravers, P., et al. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05599-w · Cited by 235
Doi, A. M., Pignatari, A. C. C., Edmond, M. B., Marra, A. R., Camargo, L. F. A., Siqueira, R. A., da Mota, V. P., & Colombo, A. L. (2016) · PLOS ONE · doi:10.1371/journal.pone.0146909 · Cited by 215
Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
Multidrug-resistant Candida auris: ‘New kid on the block’ in hospital-associated infections?
Chowdhary, A., Voss, A., & Meis, J. F. (2016) · Journal of Hospital Infection · doi:10.1016/j.jhin.2016.08.004 · Cited by 214
Vallabhaneni, S., Cleveland, A. A., Farley, M. M., Harrison, L. H., Schaffner, W., Beldavs, Z. G., Derado, G., Pham, C. D., Lockhart, S. R., & Smith, R. M. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv163 · Cited by 187
“Although this study is population-based surveillance, fi ndings from these surveillance areas may not be generalizable to the entire United States.”
BackgroundInfluentialEpidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus
Gonçalves, S. S., Souza, A. C. R., Chowdhary, A., Meis, J. F., & Colombo, A. L. (2016) · Mycoses · doi:10.1111/myc.12469 · Cited by 180
Andes, D. R., Safdar, N., Baddley, J. W., Alexander, B., Brumble, L., Freifeld, A., Hadley, S., Herwaldt, L., Kauffman, C., Lyon, G. M., et al. (2016) · Transplant Infectious Disease · doi:10.1111/tid.12613 · Cited by 182
“Examination of antifungal choice for prophylaxis and therapy in the current population revealed a use pattern consistent with prior surveys.(12,21,55,56) Prophylaxis was dominated by the triazole class, predominantly fluconazole.”
Self-citationNami, S., Aghebati-Maleki, A., Morovati, H., & Aghebati-Maleki, L. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.009 · Cited by 160
Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis
Pfaller, M. A., & Castanheira, M. (2015) · Medical Mycology · doi:10.1093/mmy/myv076 · Cited by 161
“krusei cause a disproportionate number of infections in hematopoietic stem cell transplant (HSCT) recipients where azole prophylaxis is common [8,98,108,114].”
BackgroundSelf-citationChanging epidemiology of candidaemia in Australia
Chapman, B., Slavin, M., Marriott, D., Halliday, C., Kidd, S., Arthur, I., Bak, N., Heath, C. H., Kennedy, K., Morrissey, C. O., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw422 · Cited by 163
Current perspective on emergence, diagnosis and drug resistance in Candida auris
Sarma, S., & Upadhyay, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s116229 · Cited by 146
Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002-20121
Strollo, S., Lionakis, M. S., Adjemian, J., Steiner, C. A., & Prevots, D. R. (2016) · Emerging Infectious Diseases · doi:10.3201/eid2301.161198 · Cited by 129
“Although candidemia has been described as the most common manifestation of invasive candidiasis, deep-seated infections of organs or other sites, such as the liver, spleen, heart valves, or eye, might also occur after a bloodstream infection and persist after clearance of fungi from the bloodstream (1,7).”
BackgroundCandida glabrata: A Lot More Than Meets the Eye
Kumar, K., Askari, F., Sahu, M. S., & Kaur, R. (2019) · Microorganisms · doi:10.3390/microorganisms7020039 · Cited by 128
“glabrata bloodstream infections are commonly found in elderly individuals, diabetic patients and solid organ transplant recipients [6,8,9].”
BackgroundPfaller, M. A., Rhomberg, P. R., Messer, S. A., Jones, R. N., & Castanheira, M. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2015.04.008 · Cited by 127
Self-citationFlorio, W., Tavanti, A., Barnini, S., Ghelardi, E., & Lupetti, A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01097 · Cited by 134
Souza, A. C. R., Fuchs, B. B., Pinhati, H. M. S., Siqueira, R. A., Hagen, F., Meis, J. F., Mylonakis, E., & Colombo, A. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01177-15 · Cited by 121
Mechanisms of Pathogenic Candida Species to Evade the Host Complement Attack
Singh, D. K., Tóth, R., & Gácser, A. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00094 · Cited by 135
Mejia-Chew, C., O'Halloran, J. A., Olsen, M. A., Stwalley, D., Kronen, R., Lin, C., Salazar, A. S., Larson, L., Hsueh, K., Powderly, W. G., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30405-0 · Cited by 113
Sugar Sensing and Signaling in Candida albicans and Candida glabrata
Van Ende, M., Wijnants, S., & Van Dijck, P. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00099 · Cited by 103
“Furthermore, the introduction of the antifungal fluconazole caused an increase in infections initiated by the inherently more fluconazole tolerant species, Candida glabrata (Pfaller et al., 2005; Diekema et al., 2012; Pfaller et al., 2014).”
BackgroundInvasive candidiasis species distribution and trends, United States, 2009-2017
Ricotta, E. E., Lai, Y. L., Babiker, A., Strich, J. R., Kadri, S. S., Lionakis, M. S., Prevots, D. R., & Adjemian, J. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa502 · Cited by 114
The role of Lactobacillus species in the control of Candida via biotrophic interactions
Zangl, I., Pap, I.-J., Aspöck, C., & Schüller, C. (2020) · Microbial Cell · doi:10.15698/mic2020.01.702 · Cited by 124
Grossman, N. T., Pham, C. D., Cleveland, A. A., & Lockhart, S. R. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04613-14 · Cited by 112
Xiao, Z., Wang, Q., Zhu, F., & An, Y. (2019) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-019-0534-2 · Cited by 107
“However, the proportion of non-Candida albicans strains has increased rapidly in recent years [11].”
BackgroundChew, S. Y., Chee, W. J. Y., & Than, L. T. L. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0546-5 · Cited by 101
Da Matta, D., Souza, A., & Colombo, A. (2017) · Journal of Fungi · doi:10.3390/jof3020024 · Cited by 104
Castanheira, M., Deshpande, L. M., Messer, S. A., Rhomberg, P. R., & Pfaller, M. A. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.09.003 · Cited by 105
Self-citationPinhati, H. M. S., Casulari, L. A., Souza, A. C. R., Siqueira, R. A., Damasceno, C. M. G., & Colombo, A. L. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1767-9 · Cited by 102
“ond most commonly encountered non-Candida albicans species [13].”
BackgroundIn Vitro Interactions of Echinocandins with Triazoles against Multidrug-Resistant Candida auris
Fakhim, H., Chowdhary, A., Prakash, A., Vaezi, A., Dannaoui, E., Meis, J. F., & Badali, H. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01056-17 · Cited by 102
Activity of Novel Synthetic Peptides against Candida albicans
Lum, K. Y., Tay, S. T., Le, C. F., Lee, V. S., Sabri, N. H., Velayuthan, R. D., Hassan, H. H., & Sekaran, S. D. (2015) · Scientific Reports · doi:10.1038/srep09657 · Cited by 110
Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study
Leroy, O., Bailly, S., Gangneux, J.-P., Mira, J.-P., Devos, P., Dupont, H., Montravers, P., Perrigault, P.-F., Constantin, J.-M., Guillemot, D., et al. (2016) · Annals of Intensive Care · doi:10.1186/s13613-015-0103-7 · Cited by 102
“glabrata, which is the leading non-albicans pathogen in France [19, 21], in Northern European countries [22–24], and in the US [11, 25].”
BackgroundUncommon Candida Species Fungemia among Cancer Patients, Houston, Texas, USA
Jung, D. S., Farmakiotis, D., Jiang, Y., Tarrand, J. J., & Kontoyiannis, D. P. (2015) · Emerging Infectious Diseases · doi:10.3201/eid2111.150404 · Cited by 97
Drug resistance mechanisms and their regulation in non-albicans Candida species
Kołaczkowska, A., & Kołaczkowski, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv445 · Cited by 87
Singh, A. K., Singh, P. K., de Groot, T., Kumar, A., Mathur, P., Tarai, B., Sachdeva, N., Upadhyaya, G., Sarma, S., Meis, J. F. G. M., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz029 · Cited by 87
Current methods for identifying clinically important cryptic Candida species
Criseo, G., Scordino, F., & Romeo, O. (2015) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2015.02.004 · Cited by 96
“The increasing incidence of Candida infections observed in recent years is the result of many factors, most notably the rise of severely immunocompromised patients (Pfaller et al., 2014).”
BackgroundInfluentialPfaller, M. A., Messer, S. A., Rhomberg, P. R., Borroto-Esoda, K., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00161-17 · Cited by 84
“glabrata (67) SCY-078 1 (1) 4 (2) 29 (4) 24 (10) 2 (2) 6 (5) 1 (1) Anidulafungin 2 (1) 8 (1) 23 8 4 (3) 3 (3) 7 (5) 6 (6) 6 (6) Caspofungin 14 (1) 20 (2) 7 (1) 5 (3) 7 (7) 3 (1) 6 (5) 1 (1) 2 (2) 2 (2) Micafungin 2 (1) 22 20 (4) 5 (3) 4 (3) 3 (3) 2 (2) 4 (4) 4 (4) 1 (1)”
Self-citationDominguez, E., Zarnowski, R., Sanchez, H., Covelli, A. S., Westler, W. M., Azadi, P., Nett, J., Mitchell, A. P., & Andes, D. R. (2018) · mBio · doi:10.1128/mbio.00451-18 · Cited by 77
Self-citationVaezi, A., Fakhim, H., Khodavaisy, S., Alizadeh, A., Nazeri, M., Soleimani, A., Boekhout, T., & Badali, H. (2017) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2017.02.007 · Cited by 78
Posteraro, B., Spanu, T., Fiori, B., De Maio, F., De Carolis, E., Giaquinto, A., Prete, V., De Angelis, G., Torelli, R., D'Inzeo, T., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00285-15 · Cited by 72
“The percentages of resistance reported in our study are similar to those reported from two recent Spanish studies (38, 45), showing that resistance to echinocandins is not emerging like it is in other geographical areas, such as the United States (15, 35).”
BackgroundInfluentialRobust Extracellular pH Modulation by Candida albicans during Growth in Carboxylic Acids
Danhof, H. A., Vylkova, S., Vesely, E. M., Ford, A. E., Gonzalez-Garay, M., & Lorenz, M. C. (2016) · mBio · doi:10.1128/mbio.01646-16 · Cited by 72
Posteraro, B., Efremov, L., Leoncini, E., Amore, R., Posteraro, P., Ricciardi, W., & Sanguinetti, M. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00802-15 · Cited by 97
Recurrent candidal intertrigo: challenges and solutions
Metın, A., Dılek, N., & Bilgili, S. G. (2018) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s127841 · Cited by 72
“guilliermondii.(33) Each of these organisms exhibits characteristic virulence potential, antifungal susceptibility, and epidemiology.”
BackgroundWang, F.-J., Zhang, D., Liu, Z.-H., Wu, W.-X., Bai, H.-H., & Dong, H.-Y. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.181964 · Cited by 71
“However, the possibility of some system bias cannot be excluded due to the potential reasons of the different specimen, test method, and regional disparity.[5,13,14,17,19,20]”
BackgroundLombardi, L., Maisetta, G., Batoni, G., & Tavanti, A. (2015) · Molecules · doi:10.3390/molecules20046319 · Cited by 71
“of treatment, currently represents a major concern in the management of mycoses, thus boosting the research for new potential antimicrobial compounds [73].”
BackgroundCandidemia in the Intensive Care Unit
Epelbaum, O., & Chasan, R. (2017) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2017.04.010 · Cited by 78
Khan, Z., Ahmad, S., Al-Sweih, N., Mokaddas, E., Al-Banwan, K., Alfouzan, W., Al-Obaid, I., Al-Obaid, K., Asadzadeh, M., Jeragh, A., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0216250 · Cited by 65
What are the 100 most cited fungal genera?
Bhunjun, C. S., Chen, Y. J., Phukhamsakda, C., Boekhout, T., Groenewald, J. Z., McKenzi, E. H. C., Francisco, E. C., Frisvad, J. C., Groenewald, M., Hurdeal, V. G., et al. (2024) · Studies in Mycology · doi:10.3114/sim.2024.108.01 · Cited by 77
Al-Dorzi, H. M., Sakkijha, H., Khan, R., Aldabbagh, T., Toledo, A., Ntinika, P., Al Johani, S. M., & Arabi, Y. M. (2020) · Journal of Intensive Care Medicine · doi:10.1177/0885066618767835 · Cited by 61
“participating sites.(36) Historical data indicated that factors associated with increased non-albicans risk were major postoperative cases, gastrointestinal procedure, enteric bacteremia, hemodialysis days, total parenteral nutrition, and number of red blood cell transfusions.”
BackgroundA common vesicle proteome drives fungal biofilm development
Zarnowski, R., Sanchez, H., Jaromin, A., Zarnowska, U. J., Nett, J. E., Mitchell, A. P., & Andes, D. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211424119 · Cited by 63
Self-citationPre-clinical Imaging of Invasive Candidiasis Using ImmunoPET/MR
Morad, H. O. J., Wild, A., Wiehr, S., Davies, G. E., Maurer, A., Pichler, B. J., & Thornton, C. R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01996 · Cited by 71
“While non-albicans Candida species have emerged as pathogens of immuno-compromised individuals over recent years (Chi et al., 2011; Papon et al., 2013; Pfaller et al., 2014), Candida albicans remains the most common cause of mucosal and systemic infections and is responsible for up to 70% of cases worldwide (Diekema e…”
BackgroundInfluentialVu, B. G., Thomas, G. H., & Moye-Rowley, W. S. (2019) · mBio · doi:10.1128/mbio.00934-19 · Cited by 59
Du, J., Wang, X., LUO, H.-X., Wang, Y., Liu, X., & Zhou, X. (2018) · BMC Veterinary Research · doi:10.1186/s12917-018-1564-3 · Cited by 57
Kobayashi, T., Marra, A. R., Schweizer, M. L., Eyck, P. T., Wu, C., Alzunitan, M. A., Salinas, J. L., Siegel, M., Farmakiotis, D., Auwaerter, P. G., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa270 · Cited by 59
Self-citationCosta Silva, R. A., da Silva, C. R., de Andrade Neto, J. B., da Silva, A. R., Campos, R. S., Sampaio, L. S., do Nascimento, F. B. S. A., da Silva Gaspar, B., da Cruz Fonseca, S. G., Josino, M. A. A., et al. (2017) · Microbial Pathogenesis · doi:10.1016/j.micpath.2017.04.008 · Cited by 56
The Economic Impact of Rapid Candida Species Identification by T2Candida Among High-Risk Patients
Bilir, S. P., Ferrufino, C. P., Pfaller, M. A., & Munakata, J. (2015) · Future Microbiology · doi:10.2217/fmb.15.29 · Cited by 58
Self-citationFluconazole-Resistant Candida glabrata Bloodstream Isolates, South Korea, 2008–2018
Won, E. J., Choi, M. J., Kim, M., Yong, D., Lee, W. G., Uh, Y., Kim, T. S., Byeon, S. A., Lee, S. Y., Kim, S. H., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2703.203482 · Cited by 59
Characterization of Virulence-Related Phenotypes in Candida Species of the CUG Clade
Priest, S. J., & Lorenz, M. C. (2015) · Eukaryotic Cell · doi:10.1128/ec.00062-15 · Cited by 48
“tropicalis is usually cited as the third or fourth most common cause of invasive infections (2, 4, 25), this species performs about as well as C.”
BackgroundDeciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?
Soulountsi, V., Schizodimos, T., & Kotoulas, S. (2021) · Infection · doi:10.1007/s15010-021-01640-7 · Cited by 59
Rybak, J. M., Dickens, C. M., Parker, J. E., Caudle, K. E., Manigaba, K., Whaley, S. G., Nishimoto, A. T., Luna-Tapia, A., Roy, S., Zhang, Q., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00651-17 · Cited by 53
Candida Bloodstream Infections in Italy: Changing Epidemiology during 16 Years of Surveillance
Caggiano, G., Coretti, C., Bartolomeo, N., Lovero, G., De Giglio, O., & Montagna, M. T. (2015) · BioMed Research International · doi:10.1155/2015/256580 · Cited by 49
“Over the past 20 years, a shift toward non-albicans Candida species has been reported [1, 29], but the precise pattern of causative species varies across countries; hence epidemiological information available for one centre may not be applicable to others.”
BackgroundResultAl-Baqsami, Z. F., Ahmad, S., & Khan, Z. (2020) · Scientific Reports · doi:10.1038/s41598-020-63240-z · Cited by 49
Klotz, U., Schmidt, D., Willinger, B., Steinmann, E., Buer, J., Rath, P., & Steinmann, J. (2016) · Mycoses · doi:10.1111/myc.12472 · Cited by 49
Kovács, R., Bozó, A., Gesztelyi, R., Domán, M., Kardos, G., Nagy, F., Tóth, Z., & Majoros, L. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.01.007 · Cited by 53
Typing and virulence factors of food-borne Candida spp. isolates
Rajkowska, K., & Kunicka‐Styczyńska, A. (2018) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2018.05.002 · Cited by 56
Biswas, C., Marcelino, V. R., Van Hal, S., Halliday, C., Martinez, E., Wang, Q., Kidd, S., Kennedy, K., Marriott, D., Morrissey, C. O., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02946 · Cited by 49
The epidemiology of Candida species in the Middle East and North Africa
Ghazi, S., Rafei, R., Osman, M., El Safadi, D., Mallat, H., Papon, N., Dabboussi, F., Bouchara, J.-P., & Hamze, M. (2019) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2019.07.006 · Cited by 50
Wiederhold, N. P., Najvar, L. K., Fothergill, A. W., Bocanegra, R., Olivo, M., McCarthy, D. I., Fukuda, Y., Mitsuyama, J., & Patterson, T. F. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv398 · Cited by 48
Eliakim‐Raz, N., Babaoff, R., Yahav, D., Yanai, S., Shaked, H., & Bishara, J. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.09.018 · Cited by 51
Paul, S., Bair, T. B., & Moye-Rowley, W. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03921-14 · Cited by 45
Insights into the role of sterol metabolism in antifungal drug resistance: a mini-review
Tanwar, S., Kalra, S., & Bari, V. K. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1409085 · Cited by 47
Invasive Fungal Infections After Kidney Transplantation: A Single-center Experience
Santos, T., Aguiar, B., Santos, L., Romãozinho, C., Tomé, R., Macario, F. J. G. R. M., Alves, R., Campos, M. E. C., & Mota, A. (2015) · Transplantation Proceedings · doi:10.1016/j.transproceed.2015.03.040 · Cited by 47
Antimicrobial Stewardship Interventions in Pediatric Oncology: A Systematic Review
Muratore, E., Baccelli, F., Leardini, D., Campoli, C., Belotti, T., Viale, P., Prete, A., Pession, A., Masetti, R., & Zama, D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154545 · Cited by 45
Charsizadeh, A., Mirhendi, H., Nikmanesh, B., Eshaghi, H., & Makimura, K. (2018) · Mycoses · doi:10.1111/myc.12698 · Cited by 42
Diba, K., Makhdoomi, K., Nasri, E., Vaezi, A., Javidnia, J., Gharabag, D. J., Jazani, N. H., Chavshin, A. R., Badiee, P., Badali, H., et al. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.09.026 · Cited by 47
Public Health Research Priorities for Fungal Diseases: A Multidisciplinary Approach to Save Lives
Smith, D. J., Gold, J. A. W., Benedict, K., Wu, K., Lyman, M., Jordan, A., Medina, N., Lockhart, S. R., Sexton, D. J., Chow, N. A., et al. (2023) · Journal of Fungi · doi:10.3390/jof9080820 · Cited by 49
Kerkoub, N., Panda, S. K., Yang, M.-R., Lu, J., Jiang, Z., Nasri, H., & Luyten, W. H. M. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01418 · Cited by 45
“, intravascular and urinary catheters, as well as implanted prostheses), and the increased use of broad-spectrum antimicrobial as well as immunosuppressive therapies (Kojic and Darouiche, 2004; Pfaller et al., 2014; Nett and Andes, 2015).”
BackgroundIdentification of Cryptic Species of Four Candida Complexes in a Culture Collection
Fontecha, G. A., Montes, K., Ortíz, B., Galindo, C., & Braham, S. (2019) · Journal of Fungi · doi:10.3390/jof5040117 · Cited by 44
“Candida albicans is the most virulent and commonly isolated species from clinical samples, even though the reports of non-albicans species are increasing [9,10].”
BackgroundMetabolic profiling of Candida clinical isolates of different species and infection sources
Oliver, J. C., Laghi, L., Parolin, C., Foschi, C., Marangoni, A., Liberatore, A., Dias, A. L. T., Cricca, M., & Vitali, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-73889-1 · Cited by 44
Yadav, T. C., Gupta, P., Saini, S., Mohiyuddin, S., Pruthi, V., & Prasad, R. (2022) · ACS Omega · doi:10.1021/acsomega.1c05822 · Cited by 45
Chew, S. Y., Ho, K. L., Cheah, Y. K., Sandai, D., Brown, A. J. P., & Than, L. T. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133172 · Cited by 40
“glabrata [11,21], relatively little is known about the physiological behaviour of C.”
BackgroundGupta, P., Goel, A., Singh, K. R., Meher, M. K., Gulati, K., & Poluri, K. M. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.035 · Cited by 41
Verma, N., Singh, S., Singh, M., Chauhan, A., Pradhan, P., Jaiswal, N., Chakrabarti, A., & Singh, M. (2021) · Mycoses · doi:10.1111/myc.13387 · Cited by 41
Gómez-Molero, E., de Boer, A. D., Dekker, H. L., Moreno-Martínez, A., Kraneveld, E. A., Ichsan, Chauhan, N., Weig, M., de Soet, J. J., de Koster, C. G., et al. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov098 · Cited by 39
Florio, W., Tavanti, A., Ghelardi, E., & Lupetti, A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02577 · Cited by 41
“albicans remains the most frequently isolated species, other fungal pathogens have been isolated with remarkably increasing frequency; these include Candida glabrata (Cleveland et al., 2012; Pfaller et al., 2014), the emerging pathogen Candida auris (Bao et al.”
BackgroundCandida lusitaniae in Kuwait: Prevalence, antifungal susceptibility and role in neonatal fungemia
Khan, Z., Ahmad, S., Al-Sweih, N., Khan, S., & Joseph, L. (2019) · PLOS ONE · doi:10.1371/journal.pone.0213532 · Cited by 34
Khosravi, A., Sharifzadeh, A., Nikaein, D., Almaie, Z., & Gandomi, H. (2018) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2018.01.005 · Cited by 45
Kodedová, M., Valachovič, M., Csáky, Z., & Sychrová, H. (2019) · Cellular Microbiology · doi:10.1111/cmi.13093 · Cited by 37
“The widespread and prolonged use of antifungals in recent years has led to the rapid emergence of multidrug‐ resistant (MDR) strains of various Candida species (Pfaller et al., 2014).”
BackgroundStavrou, A. A., Hansen, A. P., Lackner, M., Lass‐Flörl, C., & Boekhout, T. (2020) · Medical Mycology · doi:10.1093/mmy/myaa005 · Cited by 38
Candida diagnostic techniques: a review
Arafa, S., Elbanna, K., Osman, G. E. H., & Abulreesh, H. H. (2023) · Journal of Umm Al-Qura University for Applied Sciences · doi:10.1007/s43994-023-00049-2 · Cited by 43
“Mycoses (fungal infections) are characterized by high morbidity and mortality, which affect a huge global population every year [1–5].”
Background
Metadata
- Authors
- Pfaller, M. A., Andes, D. R., Diekema, D. J., Horn, D. L., Reboli, A. C., Rotstein, C., Franks, B., & Azie, N. E.
- Affiliations
- University of Iowa (US)
- University of Wisconsin–Madison (US)
- Cooper Medical School of Rowan University (US)
- University of Toronto (CA)
- Astellas Pharma (United States) (US)
- Corresponding author
- Pfaller, Michael A.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-07-03
- Volume
- 9
- Issue
- 7
- Pages
- e101510
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4081561
- OpenAlex
- W2053909542
- Cited by
- 396
- References
- 69
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 21 · 2023: 33 · 2022: 34 · 2021: 33 · 2020: 47 · 2019: 48 · 2018: 41 · 2017: 43 · 2016: 39 · 2015: 34 · 2014: 4
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Pfizer
- Massachusetts General Hospital
- University of Nebraska Medical Center
- University of Miami
- University of Pennsylvania
- Emory University
- Bunning Food Allergy Institute, Ann and Robert H. Lurie Children's Hospital of Chicago
- University of Minnesota
- University of Washington
- Johns Hopkins University
- University of Pittsburgh
- Hamilton Health Sciences
- Thomas Jefferson University
- University of Arkansas for Medical Sciences
- City of Hope
- Astellas Pharma
- University of Texas MD Anderson Cancer Center
- Medical Center, University of Pittsburgh
- National Institute of Allergy and Infectious Diseases
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Keywords
- invasive candidiasis, non-albicans Candida, Candida glabrata, Candida parapsilosis, Candida tropicalis, Candida krusei, Candida lusitaniae, Candida dubliniensis, Candida guilliermondii, Candida species distribution, antifungal therapy, fluconazole, echinocandins, 90-day survival, solid organ transplant recipients, solid tumors
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Child, Child, Preschool, Drug Therapy, Combination, Female, Humans, Infant, Male, Middle Aged, Prospective Studies, Registries, Fluconazole, Prevalence, Survival Rate, Treatment Outcome, Echinocandins, Young Adult, Candidiasis, Invasive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
